Overview
About InnoCon Medical
InnoCon Medical’s UCon System is a patented neuromodulation approach designed to address symptoms of overactive bladder and bowel dysfunction.
Unlike currently available neuromodulation therapies, UCon targets the dorsal genital nerve (DGN). Targeting DGN offers a unique opportunity for on-demand (urge) stimulation. On-demand stimulation mode lets patients activate therapy precisely when the urge hits, ideally giving them more control and time to reach a toilet.
The system offers two electrode options:
Patch Electrode: a non-invasive, replaceable option suitable for daily use and initial screening.
Bar Electrode: a long-term, partially implantable alternative, designed for permanent placement but removable when needed, e.g., for MRI scans.
UCon is being developed to provide patients and healthcare systems a more cost-effective and therefore accessible alternative compared to other sacral and tibial implantable neuromodulation systems.
To learn more, visit: innoconmedical.com
CAUTION: The UCon System is currently under clinical investigation and limited by law to investigational use only.
---
Privacy statement:
By visiting and interacting with this company page, LinkedIn will process your personal data as described in the Joint Controller Addendum (https://legal.linkedin.com/pages-joint-controller-addendum) and in the Privacy Policy (https://www.linkedin.com/legal/privacy-policy). InnoCon Medical uses the data of visitors on this page for marketing purposes. InnoCon Medical jointly controls personal data with LinkedIn.
InnoCon Medical contact details:
Address: Lyngvej 1, 9000 Aalborg
CVR: 38635794
Telephone: +45 9398 7033
Email: [email protected]
Website: www.innoconmedical.com
Contact person: Jesper Nielsen, CEO
Unlike currently available neuromodulation therapies, UCon targets the dorsal genital nerve (DGN). Targeting DGN offers a unique opportunity for on-demand (urge) stimulation. On-demand stimulation mode lets patients activate therapy precisely when the urge hits, ideally giving them more control and time to reach a toilet.
The system offers two electrode options:
Patch Electrode: a non-invasive, replaceable option suitable for daily use and initial screening.
Bar Electrode: a long-term, partially implantable alternative, designed for permanent placement but removable when needed, e.g., for MRI scans.
UCon is being developed to provide patients and healthcare systems a more cost-effective and therefore accessible alternative compared to other sacral and tibial implantable neuromodulation systems.
To learn more, visit: innoconmedical.com
CAUTION: The UCon System is currently under clinical investigation and limited by law to investigational use only.
---
Privacy statement:
By visiting and interacting with this company page, LinkedIn will process your personal data as described in the Joint Controller Addendum (https://legal.linkedin.com/pages-joint-controller-addendum) and in the Privacy Policy (https://www.linkedin.com/legal/privacy-policy). InnoCon Medical uses the data of visitors on this page for marketing purposes. InnoCon Medical jointly controls personal data with LinkedIn.
InnoCon Medical contact details:
Address: Lyngvej 1, 9000 Aalborg
CVR: 38635794
Telephone: +45 9398 7033
Email: [email protected]
Website: www.innoconmedical.com
Contact person: Jesper Nielsen, CEO